<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/21/355–1" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/21/355–1/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/21/355–1/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_355_1"><akn:num>355–1</akn:num><akn:heading>Risk evaluation and mitigation strategies</akn:heading><akn:content><akn:p>§ 355–1. Risk evaluation and mitigation strategies(a) Submission of proposed strategy(1) Initial approvalIf the Secretary, in consultation with the office responsible for reviewing the drug and the office responsible for postapproval safety with respect to the drug, determines that a risk evaluation and mitigation strategy is necessary to ensure that the benefits of the drug outweigh the risks of the drug, and informs the person who submits such application of such determination, then such person shall submit to the Secretary as part of such application a proposed risk evaluation and mitigation strategy. In making such a determination, the Secretary shall consider the following factors:(A) The estimated size of the population likely to use the drug involved.

(B) The seriousness of the disease or condition that is to be treated with the drug.

(C) The expected benefit of the drug with respect to such disease or condition.

(D) The expected or actual duration of treatment with the drug.

(E) The seriousness of any known or potential adverse events that may be related to the drug and the background incidence of such events in the population likely to use the drug.

(F) Whether the drug is a new molecular entity.


(2) Postapproval requirement(A) In generalIf the Secretary has approved a covered application (including an application approved before the effective date of this section) and did not when approving the application require a risk evaluation and mitigation strategy under paragraph (1), the Secretary, in consultation with the offices described in paragraph (1), may subsequently require such a strategy for the drug involved (including when acting on a supplemental application seeking approval of a new indication for use of the drug) if the Secretary becomes aware of new safety information and makes a determination that such a strategy is necessary to ensure that the benefits of the drug outweigh the risks of the drug.


(B) Submission of proposed strategyNot la</akn:p></akn:content><akn:subsection eId="subsec_355_1_a"><akn:num>(a)</akn:num><akn:heading>Submission of proposed strategy</akn:heading><akn:content><akn:p>(a) Submission of proposed strategy</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355_1_b"><akn:num>(b)</akn:num><akn:heading>Definitions</akn:heading><akn:content><akn:p>(b) Definitions For purposes of this section:</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355_1_c"><akn:num>(c)</akn:num><akn:heading>Contents</akn:heading><akn:content><akn:p>(c) Contents A proposed risk evaluation and mitigation strategy under subsection (a) shall—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355_1_d"><akn:num>(d)</akn:num><akn:heading>Minimal strategy</akn:heading><akn:content><akn:p>(d) Minimal strategy For purposes of subsection (c)(1), the risk evaluation and mitigation strategy for a drug shall require a timetable for submission of assessments of the strategy that—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355_1_e"><akn:num>(e)</akn:num><akn:heading>Additional potential elements of strategy</akn:heading><akn:content><akn:p>(e) Additional potential elements of strategy</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355_1_f"><akn:num>(f)</akn:num><akn:heading>Providing safe access for patients to drugs with known serious risks that would otherwise be unavailable</akn:heading><akn:content><akn:p>(f) Providing safe access for patients to drugs with known serious risks that would otherwise be unavailable</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355_1_g"><akn:num>(g)</akn:num><akn:heading>Assessment and modification of approved strategy</akn:heading><akn:content><akn:p>(g) Assessment and modification of approved strategy</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355_1_h"><akn:num>(h)</akn:num><akn:heading>Review of proposed strategies; review of assessments and modifications of approved strategies</akn:heading><akn:content><akn:p>(h) Review of proposed strategies; review of assessments and modifications of approved strategies</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355_1_i"><akn:num>(i)</akn:num><akn:heading>Abbreviated new drug applications</akn:heading><akn:content><akn:p>(i) Abbreviated new drug applications</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355_1_j"><akn:num>(j)</akn:num><akn:heading>Drug Safety Oversight Board</akn:heading><akn:content><akn:p>(j) Drug Safety Oversight Board</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>